PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, the company delivers unique solutions to serve the diagnostics, life sciences, food, and applied markets. IT strategically partners with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Its dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index.

Company profile
Ticker
PKI
Exchange
Website
CEO
Prahlad Singh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Agilent • Bio-Rad Laboratories • Waters • Illumina • Avantor • Mettler-Toledo International • Bruker • Seer • Cue Health • Cytek BioSciences ...
Former names
EG&G INC
SEC CIK
Corporate docs
Subsidiaries
2Cure, LLC • BioLegend CNS, Inc. • BioLegend Ventures, LLC • BioLegend, Inc. • Caliper Life Sciences, Inc. • Cambridge Research • Dharmacon, Inc. • Horizon Discovery, Inc. • Immunodiagnostic Systems Inc. • Nexcelom Bioscience Holdings, LLC ...
IRS number
42052042
PKI stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
15 Mar 23
ARS
2023 FY
Annual report to shareholders
8 Mar 23
DEFA14A
Additional proxy soliciting materials
8 Mar 23
DEF 14A
Definitive proxy
8 Mar 23
10-K
2022 FY
Annual report
1 Mar 23
8-K
Results of Operations and Financial Condition
14 Feb 23
8-K
Results of Operations and Financial Condition
9 Jan 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Results of Operations and Financial Condition
8 Nov 22
8-K
Results of Operations and Financial Condition
17 Oct 22
Transcripts
PKI
Earnings call transcript
2022 Q3
8 Nov 22
PKI
Earnings call transcript
2022 Q2
5 Aug 22
PKI
Earnings call transcript
2022 Q1
4 May 22
PKI
Earnings call transcript
2021 Q4
2 Feb 22
PKI
Earnings call transcript
2021 Q3
3 Nov 21
PKI
Earnings call transcript
2021 Q2
29 Jul 21
PKI
Earnings call transcript
2021 Q1
5 May 21
PKI
Earnings call transcript
2020 Q4
3 Feb 21
PKI
Earnings call transcript
2020 Q3
28 Oct 20
PKI
Earnings call transcript
2020 Q2
28 Jul 20
Latest ownership filings
4
Daniel R Tereau
22 Mar 23
144
Notice of proposed sale of securities
20 Mar 23
4
Maxwell Krakowiak
17 Mar 23
4
Joel S Goldberg
21 Feb 23
4
Daniel R Tereau
21 Feb 23
4
Andrew Okun
21 Feb 23
4
Miriame Victor
21 Feb 23
4
Maxwell Krakowiak
21 Feb 23
4
Tajinder S Vohra
21 Feb 23
4
Prahlad R. Singh
21 Feb 23
Financial summary
Quarter (USD) | Jan 23 | Oct 22 | Jul 22 | Apr 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jan 23 | Jan 22 | Jan 21 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 470.75 mm | 470.75 mm | 470.75 mm | 470.75 mm | 470.75 mm | 470.75 mm |
Cash burn (monthly) | (no burn) | 12.38 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 33.79 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 436.95 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 35.3 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2022
83.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 591 |
Opened positions | 103 |
Closed positions | 42 |
Increased positions | 194 |
Reduced positions | 187 |
13F shares | Current |
---|---|
Total value | 14.84 tn |
Total shares | 105.99 mm |
Total puts | 52.00 k |
Total calls | 43.70 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 14.39 mm | $2.02 tn |
Capital Research Global Investors | 12.86 mm | $1.80 tn |
Select Equity | 9.78 mm | $1.37 tn |
T. Rowe Price Investment Management | 9.40 mm | $1.32 tn |
BLK Blackrock | 8.47 mm | $1.19 tn |
STT State Street | 5.26 mm | $737.16 bn |
Massachusetts Financial Services | 3.24 mm | $454.77 bn |
Pictet Asset Management | 3.15 mm | $441.04 bn |
Geode Capital Management | 2.54 mm | $355.28 bn |
T. Rowe Price | 2.21 mm | $309.40 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Mar 23 | Tereau Daniel R | Common Stock | Sell | Dispose S | No | Yes | 124.79 | 300 | 37.44 k | 11,611 |
20 Mar 23 | Tereau Daniel R | Common Stock | Sell | Dispose S | No | Yes | 124.01 | 5,304 | 657.75 k | 11,911 |
20 Mar 23 | Tereau Daniel R | Common Stock | Sell | Dispose S | No | Yes | 123.37 | 5,122 | 631.90 k | 17,215 |
20 Mar 23 | Tereau Daniel R | Common Stock | Sell | Dispose S | No | Yes | 121.69 | 15 | 1.83 k | 22,337 |
20 Mar 23 | Tereau Daniel R | Common Stock | Option exercise | Acquire M | No | No | 52.65 | 3,750 | 197.44 k | 22,352 |
20 Mar 23 | Tereau Daniel R | NQ Stock Option Common Stock | Option exercise | Dispose M | No | No | 52.65 | 3,750 | 197.44 k | 0 |
16 Mar 23 | Maxwell Krakowiak | Common Stock | Payment of exercise | Dispose F | No | No | 122.54 | 21 | 2.57 k | 7,524 |
16 Feb 23 | Vohra Tajinder S | Common Stock | Grant | Acquire A | No | No | 0 | 2,201 | 0.00 | 23,805 |
16 Feb 23 | Vohra Tajinder S | NQ Stock Option Common Stock | Grant | Acquire A | No | No | 133.2 | 6,333 | 843.56 k | 6,333 |
16 Feb 23 | Singh Prahlad R. | Common Stock | Grant | Acquire A | No | No | 0 | 14,272 | 0.00 | 83,016 |
News
PerkinElmer's Oxford Immunotec Secures New Approval from U.S. FDA Expanding Instrumentation for Latent Tuberculosis Detection Workflow
23 Mar 23
Earnings Scheduled For March 2, 2023
2 Mar 23
This Analyst With 90% Accuracy Rate Sees Over 26% Upside In GlobalFoundries - 5 Stock Picks From Wall Street's Most Accurate Analysts
21 Feb 23
Credit Suisse Reiterates Neutral on PerkinElmer, Maintains $160 Price Target
15 Feb 23
Baird Maintains Outperform on PerkinElmer, Lowers Price Target to $182
15 Feb 23
Press releases
Parkland Corporation Announces First Quarter 2023 Dividend
13 Mar 23
PerkinElmer Completes Divestiture of its Applied, Food and Enterprise Services Businesses
13 Mar 23
PerkinElmer Launches EnVison Nexus Multimode Plate Reader to Drive Improved Research and Discovery Workflows
24 Feb 23
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2022
14 Feb 23
PerkinElmer Board Declares Quarterly Dividend
26 Jan 23